⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3730579 | 1.00 | — | — | |
| SCHEMBL2368628 | 0.82 | — | — | |
| SCHEMBL6133075 | 0.78 | — | — | |
| SCHEMBL10794964 | 0.75 | TSHR (0.35) | — | |
| SCHEMBL4043070 | 0.74 | — | — | |
| SCHEMBL9286503 | 0.72 | — | — | |
| SCHEMBL15634 | 0.71 | — | — | |
| SCHEMBL7402083 | 0.71 | — | — | |
| SCHEMBL487461 | 0.71 | — | — | |
| SCHEMBL3467019 | 0.71 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0977730-B1 | AMINO ACID DERIVATIVES INHIBITING EXTRACELLULAR MATRIX METALLOPROTEINASE AND TNF ALPHA RELEASE | CHIESI FARMA SPA (IT) | 2003-03-12 | — | — | EP | disclosed |
| US-6344457-B1 | RHEUMATOID ARTHRITIS, OSTEOARTHRITIS, OSTEOPOROSIS, CORNEAL ULCERATION, PERIODONTITIS, GINGIVITIS OR TUMOROUS INVASION AND METASTATIC PROLIFERATION, ATHEROSCLEROSIS, AIDS, CHRONIC INFLAMMATORY DISEASES OF THE INTESTINE | CHIESI FARMACEUTICI S.P.A. (IT) | 2002-02-05 | — | — | US | disclosed |
| EP-0977730-A1 | AMINO ACID DERIVATIVES INHIBITING EXTRACELLULAR MATRIX METALLOPROTEINASE AND TNF ALPHA RELEASE | CHIESI FARMACEUTICI S.p.A. (IT) | 2000-02-09 | — | — | EP | disclosed |
| WO-1998047863-A1 | AMINO ACID DERIVATIVES INHIBITING EXTRACELLULAR MATRIX METALLOPROTEINASE AND TNF ALPHA RELEASE | CHIESI FARMACEUTICI S.P.A. (IT) | 1998-10-29 | — | — | WO | disclosed |